VEPA and ML-Y1 Regimen for Elderly Non-Hodgkin's Lymphoma.

    January 1994 in “ Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics ”
    Juichi Tanabe, H. Kanamori, Masaharu Matsuzaki, S Motomura, Hiroshi Mohri, T Okubo, Akinori Maruta, Fumio Kodama
    TLDR Both VEPA and ML-Y1 treatments are not effective enough for elderly non-Hodgkin's lymphoma patients.
    The study involved 32 elderly patients with non-Hodgkin's lymphoma treated with either VEPA or ML-Y1 regimens. Both regimens showed similar outcomes, with complete remission rates of 37.5% for VEPA and 31.3% for ML-Y1, and median survival durations of 20 months and 13 months, respectively. Common side effects included myelosuppression, hair loss, nausea, vomiting, and peripheral neuropathy. The study concluded that both regimens were insufficient for treating NHL in elderly patients, indicating a need for a new intensive treatment approach.
    Discuss this study in the Community →